

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

1 vial (10 doses) of freeze-dried powder and 1 vial (20 ml) of solvent.  
1 vial (25 doses) of freeze-dried powder and 1 vial (50 ml) of solvent.  
1 vial (50 doses) of freeze-dried powder and 1 vial (100 ml) of solvent.  
1 vial (100 doses) of freeze-dried powder and 1 vial (200 ml) of solvent.  
1 vial (125 doses) of freeze-dried powder and 1 vial (250 ml) of solvent.

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

**UNISTRAIN PRRS** lyophilisate and solvent for suspension for injection for pigs.

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each dose contains:

Freeze-dried powder

Live attenuated PRRSV, strain VP-046 BIS ..... 10<sup>3.5</sup>-  
10<sup>5.5</sup> CCID<sub>50</sub>

Solvent:

Phosphate buffer solution.

**3. PHARMACEUTICAL FORM**

Lyophilisate and solvent for suspension for injection.

**4. PACKAGE SIZE**

1 vial of 10 doses of freeze-dried powder and 1 vial with 20 ml of solvent.  
1 vial of 25 doses of freeze-dried powder and 1 vial with 50 ml of solvent.  
1 vial of 50 doses of freeze-dried powder and 1 vial with 100 ml of solvent.  
1 vial of 100 doses of freeze-dried powder and 1 vial with 200 ml of solvent.  
1 vial of 125 doses of freeze-dried powder and 1 vial with 250 ml of solvent.

**5. TARGET SPECIES**

Pigs.

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Intramuscular use.  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period: Zero days.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}  
Once reconstituted, use within 4 hours.

**11. SPECIAL STORAGE CONDITIONS**

Store and transport refrigerated (2°C – 8°C).  
Do not freeze.  
Keep the bottles in the outer carton in order to protect from light.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Dispose of waste material in accordance with local requirements.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

LABORATORIOS HIPRA, S.A.  
Avda. la Selva, 135  
17170 Amer (Girona)  
SPAIN

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm 17533/4016

**17. MANUFACTURER'S BATCH NUMBER**

Batch {number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

1 vial (50 doses) of freeze-dried powder and 1 vial (10 ml) of solvent.  
1 vial (100 doses) of freeze-dried powder and 1 vial (20 ml) of solvent.  
1 vial (125 doses) of freeze-dried powder and 1 vial (25 ml) of solvent.  
1 vial (250 doses) of freeze-dried powder and 1 vial (50 ml) of solvent.

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

**UNISTRAIN PRRS** lyophilisate and solvent for suspension for injection for pigs.

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each dose contains:

Freeze-dried powder

Live attenuated PRRSV, strain VP-046 BIS ..... 10<sup>3.5</sup>-  
10<sup>5.5</sup> CCID<sub>50</sub>

Solvent:

Phosphate buffer solution.

**3. PHARMACEUTICAL FORM**

Lyophilisate and solvent for suspension for injection.

**4. PACKAGE SIZE**

1 vial (50 doses) of freeze-dried powder and 1 vial (10 ml) of solvent.  
1 vial (100 doses) of freeze-dried powder and 1 vial (20 ml) of solvent.  
1 vial (125 doses) of freeze-dried powder and 1 vial (25 ml) of solvent.  
1 vial (250 doses) of freeze-dried powder and 1 vial (50 ml) of solvent.

**5. TARGET SPECIES**

Pigs.

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Intradermal use.  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period: Zero days.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}  
Once reconstituted, use within 4 hours.

**11. SPECIAL STORAGE CONDITIONS**

Store and transport refrigerated (2°C – 8°C).  
Do not freeze.  
Keep the bottles in the outer carton in order to protect from light.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Dispose of waste material in accordance with local requirements.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

LABORATORIOS HIPRA, S.A. Avda. la Selva, 135  
17170 Amer (Girona)  
SPAIN

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm 17533/4016

**17. MANUFACTURER'S BATCH NUMBER**

Batch {number}



**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

10 vials (10, 25, 50, 100 and 125 doses) of freeze-dried powder.

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

**UNISTRAIN PRRS** lyophilisate and solvent for suspension for injection for pigs.

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each dose contains:

Live attenuated PRRSV, strain VP-046 BIS ..... 10<sup>3.5</sup>-  
10<sup>5.5</sup> CCID<sub>50</sub>

**3. PHARMACEUTICAL FORM**

Lyophilisate for suspension for injection.

**4. PACKAGE SIZE**

10 vials of 10 doses.  
10 vials of 25 doses.  
10 vials of 50 doses.  
10 vials of 100 doses.  
10 vials of 125 doses.

**5. TARGET SPECIES**

Pigs.

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Intramuscular use.  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period: Zero days.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}  
Once reconstituted, use within 4 hours.

**11. SPECIAL STORAGE CONDITIONS**

Store and transport refrigerated (2°C – 8°C).  
Do not freeze.  
Keep the bottles in the outer carton in order to protect from light.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Dispose of waste material in accordance with local requirements.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

LABORATORIOS HIPRA, S.A.  
Avda. la Selva, 135  
17170 Amer (Girona)  
SPAIN

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm 17533/4016

**17. MANUFACTURER'S BATCH NUMBER**

Batch {number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

10 vials (50, 100 125 and 250 doses) of freeze-dried powder.

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

**UNISTRAIN PRRS** lyophilisate and solvent for suspension for injection for pigs.

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each dose contains:

Live attenuated PRRSV, strain VP-046 BIS ..... 10<sup>3.5</sup>-  
10<sup>5.5</sup> CCID<sub>50</sub>

**3. PHARMACEUTICAL FORM**

Lyophilisate for suspension for injection.

**4. PACKAGE SIZE**

10 vials of 50 doses.  
10 vials of 100 doses.  
10 vials of 125 doses.  
10 vials of 250 doses.

**5. TARGET SPECIES**

Pigs.

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Intradermal use.  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period: Zero days.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}  
Once reconstituted, use within 4 hours.

**11. SPECIAL STORAGE CONDITIONS**

Store and transport refrigerated (2°C – 8°C).  
Do not freeze.  
Protect from light.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Dispose of waste material in accordance with local requirements.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

LABORATORIOS HIPRA, S.A.  
Avda. la Selva, 135  
17170 Amer (Girona)  
SPAIN

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm 17533/4016

**17. MANUFACTURER'S BATCH NUMBER**

Batch {number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

10 vials (10, 20, 25 and 50 ml) of solvent

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Solvent for UNISTRAIN PRRS.

**2. STATEMENT OF ACTIVE SUBSTANCES**

**3. PHARMACEUTICAL FORM**

Solvent for suspension for injection.

**4. PACKAGE SIZE**

10 vials of 10 ml.

10 vials of 20 ml.

10 vials of 25 ml.

10 vials of 50 ml.

**5. TARGET SPECIES**

Pigs.

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Solvent for suspension for injection to be used for the reconstitution of the freeze-dried powder.

Intradermal use.

Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period: Zero days.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

**11. SPECIAL STORAGE CONDITIONS**

Store and transport below +25 °C.

Do not freeze.

Keep the bottles in the outer carton in order to protect from light.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Dispose of waste material in accordance with local requirements.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

LABORATORIOS HIPRA, S.A.  
Avda. la Selva, 135  
17170 Amer (Girona)  
SPAIN



**16. MARKETING AUTHORISATION NUMBER(S)**

Vm 17533/4016

**17. MANUFACTURER'S BATCH NUMBER**

Batch {number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

10 vials (20, 50, 100, 200 and 250 ml) of solvent

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Solvent for UNISTRAIN PRRS.

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

**3. PHARMACEUTICAL FORM**

Solvent for suspension for injection.

**4. PACKAGE SIZE**

10 vials of 20 ml.  
10 vials of 50 ml.  
10 vials of 100 ml.  
10 vials of 200 ml.  
10 vials of 250 ml.

**5. TARGET SPECIES**

Pigs.

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Solvent for suspension for injection to be used for the reconstitution of the freeze-dried powder.  
Intramuscular use.  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period: Zero days.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

**11. SPECIAL STORAGE CONDITIONS**

Store and transport below +25 °C.  
Do not freeze. Keep the bottles in the outer carton in order to protect from light.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Dispose of waste material in accordance with local requirements.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

LABORATORIOS HIPRA, S.A.  
Avda. la Selva, 135  
17170 Amer (Girona)  
SPAIN

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm 17533/4016

**17. MANUFACTURER'S BATCH NUMBER**

Batch {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

1 vial (10, 25, 50, 100 and 125 doses) of freeze-dried powder.

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

**UNISTRRAIN PRRS** lyophilisate for suspension for injection for pigs.

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Each dose contains:

Live attenuated PRRSV, strain VP-046 BIS .....  $10^{3.5-10^{5.5}}$  CCID<sub>50</sub>

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

10 doses.  
25 doses.  
50 doses.  
100 doses.  
125 doses.

**4. ROUTE(S) OF ADMINISTRATION**

Intramuscular use.  
To be reconstituted with the solvent.  
Read the package leaflet before use.

**5. WITHDRAWAL PERIOD**

Withdrawal period: Zero days.

**6. BATCH NUMBER**

Batch {number}

**7. EXPIRY DATE**

EXP {month/year}  
Once reconstituted, use within 4 hours.

**8. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

1 vial (50, 100, 125 and 250 doses) of freeze-dried powder.

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

**UNISTRRAIN PRRS** lyophilisate for suspension for injection for pigs.

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Each dose contains:

Live attenuated PRRSV, strain VP-046 BIS .....  $10^{3.5-10^{5.5}}$  CCID<sub>50</sub>

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

- 50 doses.
- 100 doses.
- 125 doses.
- 250 doses.

**4. ROUTE(S) OF ADMINISTRATION**

Intradermal use.  
To be reconstituted with the solvent.  
Read the package leaflet before use.

**5. WITHDRAWAL PERIOD**

Withdrawal period: Zero days.

**6. BATCH NUMBER**

Batch {number}

**7. EXPIRY DATE**

EXP {month/year}  
Once reconstituted, use within 4 hours.

**8. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.



**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

1 vial (10, 20, 25 and 50 ml) of solvent.

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Solvent for UNISTRAIN PRRS.

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

10 ml.  
20 ml  
25 ml  
50 ml

**4. ROUTE(S) OF ADMINISTRATION**

Solvent for suspension for injection to be used for the reconstitution of the freeze-dried powder.  
Intradermal use.  
Read the package leaflet before use.

**5. WITHDRAWAL PERIOD**

Withdrawal period: Zero days.

**6. BATCH NUMBER**

Batch {number}

**7. EXPIRY DATE**

EXP {month/year}

**8. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

1 vial (20, 50, 100, 200 and 250 ml) of solvent.

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Solvent for UNISTRAIN PRRS.

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

20 ml.  
50 ml.  
100 ml.  
200 ml  
250 ml

**4. ROUTE(S) OF ADMINISTRATION**

Solvent for suspension for injection to be used for the reconstitution of the freeze-dried powder.  
Intramuscular use  
Read the package leaflet before use.

**5. WITHDRAWAL PERIOD**

Withdrawal period: Zero days.

**6. BATCH NUMBER**

Batch {number}

**7. EXPIRY DATE**

EXP {month/year}

**8. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

## **B. PACKAGE LEAFLET**

## PACKAGE LEAFLET

### UNISTRAIN PRRS

Lyophilisate and solvent for suspension for injection for pigs.

#### **1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder and manufacturer responsible for batch release:

Laboratorios Hipra, S.A.

Avda. la Selva, 135

17170 Amer (Girona) SPAIN

Tel. +34 972 43 06 60 - Fax. +34 972 43 06 61

E-mail: [hipra@hipra.com](mailto:hipra@hipra.com)

#### **2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

**UNISTRAIN PRRS** lyophilisate and solvent for suspension for injection for pigs.

#### **3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)**

Each dose contains:

Freeze-dried powder:

Active substance:

Live attenuated PRRSV, strain VP-046 BIS .....

$10^{3.5}$ - $10^{5.5}$  CCID<sub>50</sub>

(*cell culture infectious dose*)

Solvent:

Phosphate buffer solution.

#### **4. INDICATION(S)**

Breeding females: For active immunisation of breeding females from farms affected with European PRRS virus to reduce reproductive disorders, incidence and duration of viraemia, transplacental virus transmission, virus tissue load and clinical signs in the offspring associated with infection with strains of PRRS virus. Under laboratory conditions, vaccination of females reduced the negative impact of PRRS virus infection on piglet performance (mortality and weight gain) within the first 28 days of life.

Onset of immunity: 30 days after vaccination.

Duration of immunity: 16 weeks after vaccination.

Pigs from 4 weeks of age: For active immunisation of pigs from farms affected with European PRRS virus to reduce clinical signs associated with a PRRS virus infection, the incidence and duration of the viraemia and the duration of virus shedding by infected animals. Under experimental conditions, it was demonstrated that vaccination reduces the virus tissue load in the lungs. Under field conditions, where a PRRSV infection occurred during the fattening period, a reduction in mortality and in the negative effects of infection on daily weight gain was demonstrated.

Onset of immunity: 28 days after vaccination.

Duration of immunity: 24 weeks after vaccination.

## **5. CONTRAINDICATIONS**

Do not use in case of hypersensitivity to the active ingredient or to any of the excipients.

Do not use in naïve herds in which the presence of European PRRSV has not been established through reliable diagnostic virological methods.

No data are available on the safety of the vaccine for the reproductive performance in boars.

## **6. ADVERSE REACTIONS**

Slight transient increases (not greater than 1.5°C) in body temperature following vaccination occurred very commonly in studies. These reactions spontaneously resolved without treatment.

Mild and transient depression or anorexia following vaccination occurred very commonly in studies. These signs disappeared spontaneously without any additional treatment.

After intradermal administration, local reactions (inflammation and/or redness) following vaccination occurred very commonly in studies. These local reactions were mild and transient, typically resolving within 2 days.

After intramuscular administration injection site reactions (small nodules and/or inflammation) following vaccination occurred commonly in studies. The lesions were mild and transient, typically resolving within one week.

Vaccination very rarely caused hypersensitivity reactions. In such cases, an appropriate symptomatic treatment should be administered.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)

- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Pigs.

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

For intramuscular or intradermal use:

- For the intramuscular route the vaccine should be given in the neck region.
- For the intradermal route:
  - o in pigs from 4 weeks of age, the vaccine can be given in the neck region,
  - o in breeding females, the vaccine can be given in the neck region, the perineal zone or the udder.

The ID device supplied by the manufacturing authorisation holder or other suitable needle-free device able to administer 0.2 ml doses (injection stream diameter of 0.25-0.30 mm and a peak force of injection of 0.9-1.3 N) should be used.

Aseptic injection techniques should be observed to avoid introduction of contamination during vaccine administration.

The following doses and administration methods should be used:

### **Pigs from 4 weeks of age:**

2 ml via intramuscular injection or 0.2 ml via intradermal administration.

### **Breeding females:**

2 ml via intramuscular injection or 0.2 ml via intradermal administration. A single vaccination should be administered once in each reproductive cycle for protection during the subsequent pregnancy.

- In gilts, administer one injection of the reconstituted vaccine per animal 4 weeks before mating.
- In sows, administer one injection of the reconstituted vaccine per animal:
  - o 2 weeks before each mating or



- at 8-9 weeks of each gestation (approximately 60 days after mating) or
- vaccinate sows every 4 months

PRRS-naïve sows should not be vaccinated during pregnancy.

## **9. ADVICE ON CORRECT ADMINISTRATION**

Reconstitute the vaccine with the corresponding solvent:

<b>N° of dose/ vial</b>	<b>Volume of solvent</b>	
	<b>IM</b>	<b>ID</b>
10 doses	20 ml	-
25 doses	50 ml	-
50 doses	100 ml	10 ml
100 doses	200 ml	20 ml
125 doses	250 ml	25 ml
250 doses	-	50 ml

If the solvent is refrigerated, it should be allowed to warm up to a temperature between 15 °C to 25 °C before reconstitution of the freeze-dried powder. Peel the aluminium capsule off the bottle containing the solvent and aspirate in order to remove a certain volume of the contents. Then inject this volume of solvent into the vial containing the freeze-dried powder. Shake until the freeze-dried powder is completely dissolved. Once reconstituted, withdraw all the suspension obtained from the vaccine vial and inject it into the vial containing the remaining solvent. Shake well before use. The reconstituted vaccine is a homogeneous reddish solution. Avoid the introduction of contamination during reconstitution and use. Use only sterile needles and syringes for administration.

For simultaneous use with ERYSENG PARVO in breeding females from 6 months of age, the mixed administration of UNISTRAN PRRS and ERYSENG PARVO should only be used when vaccinating animals prior to mating.

The following instructions should be used: the contents of a single vial of UNISTRAN PRRS should be reconstituted with the contents of a single vial of ERYSENG PARVO in the same way as described for reconstitution with solvent. A single dose (2 ml) of the mixed vaccines should be injected within a period of 2 hours via intramuscular use.

UNISTRAIN		ERYSENG
PRRS		PARVO
10 doses	+	10 doses (20 ml)
25 doses	+	25 doses (50 ml)
50 doses	+	50 doses (100 ml)

## **10. WITHDRAWAL PERIOD**

Zero days.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

Freeze-dried powder and combined packaging: Store and transport refrigerated (2° C - 8° C).

Solvent: Store and transport below +25 °C.

Do not freeze.

Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.

Shelf-life after reconstitution with solvent according to directions: within 4 hours.

Shelf life after mixing with ERYSENG PARVO: 2 hours.

## **12. SPECIAL WARNING(S)**

Special warnings for each target species:

Vaccinate healthy animals only.

Precautions should be taken to avoid the transfer of the virus within the herd, e.g. from seropositive animals to seronegative animals.

Maternally derived antibodies can interfere with the efficacy of the vaccine. In the presence of high maternally derived antibodies, timing of initial vaccination of piglets should be planned accordingly.

Special precautions for use in animals:

Vaccination should aim to achieve a homogenous immunity in the target population at farm level...

PRRS virus-naïve breeding animals (e.g. replacement gilts from PRRS virus-negative herds) which are introduced into a PRRSV-infected herd should be vaccinated prior to first insemination. Vaccination should preferably be done in a separated quarantine unit. A transition period should be respected between vaccination and moving the animals to the breeding unit. This transition period should be longer than the shedding phase of the PRRS MLV vaccine following vaccination.

Do not routinely rotate two or more commercial PRRS MLV vaccines based on different strains in a herd.

In order to limit the potential risk of recombination between PRRS MLV vaccine strains of the same genotype, do not use different PRRS MLV vaccines based on different strains of the same genotype on the same farm at the same time. In the case of transitioning from one PRRS MLV vaccine to another PRRS MLV vaccine, a transition period should be respected between the last administration of the current vaccine and the first administration of the new vaccine. This transition period should be longer than the shedding period of the current vaccine following vaccination.

The vaccine virus may be shed after vaccination e.g. in the faeces and/or in nasal or oral secretions of vaccinated animals.

Following vaccination of breeding females the vaccine strain may be shed for up to nine days. Following vaccination of 4 week old pigs, shedding of the vaccine strain may last for up to 29 days.

The vaccine strain can spread to non-vaccinated cohabitant animals, including the fetus during pregnancy and piglets after partum without any clinical consequence. Therefore, special precautions should be taken to avoid spreading to susceptible animals, if necessary.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

In case adverse reactions develop following accidental self-injection, seek medical advice and show the package leaflet or the label to the physician.

Pregnancy and lactation:

Can be used during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:

**Breeding females:**

Safety and efficacy data are available which demonstrate that this vaccine can be mixed with ERYSENG PARVO and administered at one injection site by intramuscular route. The product literature of ERYSENG PARVO should be consulted before administration of the mixed products.

The mixed administration of UNISTRAIN PRRS and ERYSENG PARVO should only be used when vaccinating animals prior to mating.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the product mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

**Pigs from 4 weeks of age:**

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the product

mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose (symptoms, emergency procedures, antidotes):

Breeding females: Negative effects in the reproductive parameters could not be excluded following the administration of a 10x overdose in naïve pregnant females, therefore PRRSV-naïve gilts or sows should not be vaccinated during pregnancy. Particular care and attention to the correct reconstitution of the vaccine and management of the vaccination procedure should be taken in order to avoid accidental overdose. Special precautions should be taken to avoid overdose in naïve pregnant females.

No adverse reactions were observed in seropositive gilts and sows or in their offspring following the administration of a 10x overdose during the 2<sup>nd</sup> or 3<sup>rd</sup> trimester of gestation. However, viremia in piglets may be uncommonly observed in seropositive sows vaccinated with a 10x overdose during the 3<sup>rd</sup> trimester of pregnancy.

Pigs from 4 weeks of age: No adverse reactions were observed in naïve piglets after an overdose administration (10 doses).

Major incompatibilities:

Do not mix with any other veterinary medicinal product, except with the solvent supplied for use with the product or with ERYSENG PARVO.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Medicines should not be disposed of via wastewater or household waste. Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

November 2021

**15. OTHER INFORMATION**

Package sizes:

Intramuscular use:

Cardboard box containing 1 vial with 10 doses of freeze-dried powder and 1 vial with 20 ml of solvent.

Cardboard box containing 1 vial with 25 doses of freeze-dried powder and 1 vial with 50 ml of solvent.

Cardboard box containing 1 vial with 50 doses of freeze-dried powder and 1 vial with 100 ml of solvent.

Cardboard box containing 1 vial with 100 doses of freeze-dried powder and 1 vial with 200 ml of solvent.

Cardboard box containing 1 vial with 125 doses of freeze-dried powder and 1 vial with 250 ml of solvent.

Cardboard box containing 10 vials with 10, 25, 50, 100 or 125 doses of freeze-dried powder.

Cardboard box containing 10 vials with 20, 50, 100, 200 or 250 ml of solvent.

Intradermal use:

Cardboard box containing 1 vial with 50 doses of freeze-dried powder and 1 vial with 10 ml of solvent.

Cardboard box containing 1 vial with 100 doses of freeze-dried powder and 1 vial with 20 ml of solvent.

Cardboard box containing 1 vial with 125 doses of freeze-dried powder and 1 vial with 25 ml of solvent.

Cardboard box containing 1 vial with 250 doses of freeze-dried powder and 1 vial with 50 ml of solvent.

Cardboard box containing 10 vials with 50, 100, 125 or 250 doses of freeze-dried powder.

Cardboard box containing 10 vials with 10, 20, 25 or 50 ml of solvent.

Not all pack sizes may be marketed.

Approved 17 February 2022

A handwritten signature in black ink, appearing to read "A. Hunter". The signature is stylized with a large, looped initial "A" and a cursive "Hunter".